SA JOURNAL OF DIABETES & VASCULAR DISEASE
REVIEW
VOLUME 7 NUMBER 1 • MARCH 2010
11
nephropathy.
29
In the Modified Diet in Renal Disease study
which largely included non-diabetic patients the benefits of a
low protein diet were inconclusive.
30
Currently, dietary protein
restriction does not form part of the routine treatment of
diabetic nephropathy in the United Kingdom.
Conclusion
Diabetic nephropathy is a progressive condition and as it
evolves the risk of cardiovascular complications increases.
The evidence for intervention is clear and mainly involves the
timely introduction of antihypertensive agents which block
the renin–angiotensin system.
No doubt the options for treatment of diabetic nephropathy
will expand in future years. For the present treatment is
limited and in the latter stages of the condition is unable
to alter the burden of cardiovascular events. Therefore, early
detection and treatment of diabetic nephropathy must be
sought and a systematic approach employed which includes
patient and healthcare staff education.
References
Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2
1.
diabetes: A medical catastrophe of worldwide dimensions.
Am J Kidney
Dis
1999;
34
: 795–808.
Adler AI, Stevens RJ, Manley SE,
2.
et al
. Development and progression
of nephropathy in type 2 diabetes: the United Kingdom Prospective
Diabetes Study (UKPDS 64).
Kidney Int
2003;
63
: 225–232.
Allen KV, Walker JD. Microalbuminuria and mortality in long-duration
3.
type 1 diabetes.
Diabetes Care
2003;
26
: 2389–2391.
Gambaro G, Kinalska I, Oksa A,
4.
et al
. Oral sulodexide reduces
albuminuria in microalbuminuric and macroalbuminuric type 1 and type
2 diabetic patients: the Di.N.A.S. randomized trial.
J Am Soc Nephrol
2002;
13
: 1615–1625.
The Diabetes Control and Complications Trial Research Group. The
5.
effect of intensive treatment of diabetes on the development and
progression of long term complications in insulin dependent diabetes
mellitus.
N Engl J Med
1993;
329
: 977–986.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose
6.
control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33).
Lancet
1998;
352
: 837–853.
Bilous R. Microvascular disease: what does the UKPDS tell us about
7.
diabetic nephropathy?
Diabetes Med
2008;
25
(suppl 2): 25–29.
National Institute for Health and Clinical Excellence. The management
8.
of type 2 diabetes. London: NICE, 2008.
Keller CK, Bergis KH, Fliser D, Ritz E. Renal findings in patients with
9.
short-term type 2 diabetes.
J Am Soc Nephrol
1996;
7
: 2627–2635.
Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus.
10.
N Engl J Med
1999;
341
: 1127–1133.
Ruggenenti P, Fassi A, Ilieva AP,
11.
et al
. Preventing microalbuminuria in
type 2 diabetes.
N Engl J Med
2004;
351
: 1941–1951.
Patel A, MacMahon S, Chalmers J,
12.
et al
. Effects of a fixed combination
of perindopril and indapamide on macrovascular and microvascular
outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):
a randomised controlled trial.
Lancet
2007;
370
: 829–840.
Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated
13.
in diabetic nephropathy: implications for an alternative pathway of
angiotensin IImediated diabetic renal and vascular disease.
J Am Soc
Nephrol
2003;
14
: 1738–1747.
Parving HH, Lehnert H, Brochner-Mortensen J,
14.
et al
. The effect of
irbesartan on the development of diabetic nephropathy in patients with
type 2 diabetes.
N Engl J Med
2001;
345
: 870–878.
Makino H, Haneda M, Babazono T,
15.
et al
. Prevention of transition from
incipient to overt nephropathy with telmisartan in patients with type 2
diabetes.
Diabetes Care
2007;
30
: 1577–1578.
Mogensen CE, Neldam S, Tikkanen I,
16.
et al
. Randomised controlled
trial of dual blockade of renin–angiotensin system in patients with
hypertension, microalbuminuria, and non-insulin dependent diabetes:
the candesartan and lisinopril microalbuminuria (CALM) study.
Br Med
J
2000;
321
: 1440–1444.
Parving HH, Persson F, Lewis JB,
17.
et al
. Aliskiren combined with losartan in
type 2 diabetes and nephropathy.
N Engl J Med
2008;
358
: 2433–2446.
Barnett AH, Bain SC, Bouter P,
18.
et al
. Angiotensin-receptor blockade
versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
N Engl J Med
2004;
351
: 1952–1961.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-
19.
converting-enzyme inhibitionondiabetic nephropathy. TheCollaborative
Study Group.
N Engl J Med
1993;
329
: 1456–1462.
Lewis EJ, Hunsicker LG, Clarke WR,
20.
et al
. Renoprotective effect of the
angiotensin-receptor antagonist irbesartan in patients with nephropathy
due to type 2 diabetes.
N Engl J Med
2001;
345
: 851–860.
Brenner BM, Cooper ME, de Zeeuw D,
21.
et al
. Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes and
nephropathy.
N Engl J Med
2001;
345
: 861–869.
Staessen JA, Wang JG, Ginocchio G,
22.
et al
. The deletion/insertion
polymorphism of the angiotensin converting enzyme gene and
cardiovascular-renal risk.
J Hypertens
1997;
15
: 1579–1592.
Parving HH, de Zeeuw D, Cooper ME,
23.
et al
. ACE gene polymorphism
and losartan treatment in type 2 diabetic patients with nephropathy.
J
Am Soc Nephrol
2008;
19
: 771–779.
Penno G, Chaturvedi N, Talmud PJ,
24.
et al
. Effect of angiotensin-
converting enzyme (ACE) gene polymorphism on progression of renal
disease and the influence of ACE inhibition in IDDM patients: findings
from the EUCLID Randomized Controlled Trial. EURODIAB Controlled
Trial of Lisinopril in IDDM.
Diabetes
1998;
47
: 1507–1511.
Fujisawa T, Ikegami H, Kawaguchi Y,
25.
et al
. Meta-analysis of association
of insertion/deletion polymorphism of angiotensin I-converting enzyme
gene with diabetic nephropathy and retinopathy.
Diabetologia
1998;
41
: 47–53.
Ritz E, Ogata H, Orth SR. Smoking: a factor promoting onset and
26.
progression of diabetic nephropathy.
Diabetes Metab
2000;
26
(suppl
4): 54–63.
Wanner C, Krane V, Marz W,
27.
et al
. Atorvastatin in patients with type
2 diabetes mellitus undergoing hemodialysis.
N Engl J Med
2005;
353
:
238–248.
Tonolo G, Ciccarese M, Brizzi P,
28.
et al
. Reduction of albumin excretion
rate in normotensive microalbuminuric type 2 diabetic patients during
long-term simvastatin treatment.
Diabetes Care
1997;
20
: 1891–1895.
Pedrini MT, Levey AS, Lau J,
29.
et al
. The effect of dietary protein restriction
on the progression of diabetic and nondiabetic renal diseases: a meta-
analysis.
Ann Intern Med
1996;
124
: 627–632.
Klahr S, Levey AS, Beck GJ,
30.
et al
. The effects of dietary protein restriction
and blood-pressure control on the progression of chronic renal disease.
Modification of Diet in Renal Disease Study Group.
N Engl J Med
1994;
330
: 877–884.
Key messages
Diabetic nephropathy is a progressive condition with
•
high cardiovascular morbidity and mortality
Progression can be slowed by timely introduction of an-
•
tihypertensive medications particularly those that block
the renin-angiotensin system
General cardiovascular risk reduction measures are im-
•
portant in patients with diabetic nephropathy
